Medtronic plc
For the period ended Oct 15, 2026. Filed Aug 17, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Oct 15, 2026 · Filed Aug 17, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
| ☒ | Filed by the Registrant | ☐ | Filed by a Party other than the Registrant |
|---|
| Check the appropriate box: | |
|---|---|
| ☐ | Preliminary Proxy Statement |
| ☐ | CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material Pursuant to §240.14a-12 |
®
Medtronic plc
(Name of Registrant as specified in its charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
| Payment of Filing Fee (Check all boxes that apply): | |
|---|---|
| ☒ | No fee required. |
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
2022 Proxy Statement and Notice of Annual Meeting of Shareholders
PROXY
STATEMENT
and Notice of 2026 Annual General Meeting of Shareholders
Thursday, October 15, 2026 -8:00 a.m. local time - Galway, Ireland
Notice of Annual General Meeting
Thursday, October 15, 2026
8:00 a.m. local time
The Galmont Hotel & Spa, Lough Atalia Rd., Galway, H91 CYN3, Ireland
MEETING AGENDA
Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2027 Annual General Meeting of Medtronic plc (Medtronic or the Company);
Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP (PricewaterhouseCoopers) as the Company’s independent auditor for the fiscal year ending April 30, 2027 (fiscal year 2027 or FY27) and authorizing, in a binding vote, the Board of Directors (the Board), acting through the Audit Committee, to set the auditor’s remuneration;
Approving, on an advisory basis, the Company’s executive compensation;
Renewing the Board of Directors’ authority to issue shares under Irish law;
Renewing the Board of Directors’ authority to opt out of pre-emption rights under Irish law;
Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares;
Receiving and considering the Company’s Irish Statutory Financial Statements for the fiscal year ended April 24, 2026 (fiscal year 2026 or FY26) and the reports of the directors and auditors thereon, and reviewing the affairs of the Company; and
Transacting any other business that may properly come before the meeting and any adjournments or postponements thereof.
Proposals 1, 2, 3, 4, and 6 above are ordinary resolutions requiring a simple majority of the votes cast at the meeting to be approved. Proposal 5 is considered a special resolution requiring at least 75% of the votes cast at the meeting to be approved. All proposals are more fully described in the proxy statement. There is no requirement under Irish law that Medtronic’s Irish Statutory Financial Statements for fiscal year 2026, or the directors’ and auditor’s reports thereon, be approved by the shareholders, and no such approval will be sought at the 2026 Annual General Meeting of the Company (Annual General Meeting).
RECORD DATE
Shareholders of record at NYSE market close on August 21, 2026, will be entitled to vote at the Annual General Meeting.
ONLINE PROXY DELIVERY AND VOTING
As permitted by the U.S. Securities and Exchange Commission (the SEC), we are making this proxy statement, the Company’s 2026 Annual Report to Shareholders, and our Irish Statutory Financial Statements available to our shareholders electronically via the Internet. We believe electronic delivery expedites your receipt of materials, reduces the environmental impact of our Annual General Meeting, and reduces costs significantly. The Notice Regarding Internet Availability of Proxy Materials (the Notice) contains instructions on how you can access the proxy materials and how to vote online. If you receive the Notice by mail, you will not receive a printed copy of the proxy materials unless you request one in accordance with the instructions provided in the Notice. The Notice will be mailed to shareholders on or about September 3, 2026.
ADMISSION TO THE ANNUAL GENERAL MEETING
If you wish to attend the Annual General Meeting, you must be a shareholder on the record date and either request an admission ticket in advanceby visitingwww.proxyvote.com and following the instructions provided (you will need the control number included on your proxy card, voter instruction form or Notice), or bring proof of ownership of ordinary shares to the meeting. Tickets will be issued to registered and beneficial owners and to one guest accompanying each registered or beneficial owner.
August 17, 2026
By Order of the Board of Directors,
/s/ Michelle Quinn
Michelle Quinn
Executive Vice President, General Counsel and Secretary
Medtronic plc
Important Notice Regarding the Availability of Proxy Materials for the Annual General Meeting of Shareholders to be held on October 15, 2026: The proxy statement, the Company’s 2026 Annual Report to Shareholders, and our Irish Statutory Financial Statements for fiscal year 2026, are available atwww.proxyvote.com.
YOUR VOTE IS IMPORTANT. WE ENCOURAGE YOU TO VOTE.
If possible, please vote your shares over the internet using the instructions found in the Notice. Alternatively, you may request a printed copy of the proxy materials and vote using the toll-free telephone number on the proxy card or by marking, signing, dating and mailing your proxy card in the postage-paid envelope that will be provided. Voting by any of these methods will not limit your right to vote during the 2026 Annual General Meeting. All proxies will be forwarded to the Company’s registered office electronically.Under New York Stock Exchange (NYSE) rules, if you hold your shares in “street” name through a brokerage account, your broker will NOT be able to vote your shares on non-routine matters being considered at the 2026 Annual General Meeting unless you have given instructions to your broker prior to the meeting on how to vote your shares. Proposals 1 and 3 are considered non-routine matters under NYSE rules. This means that you must give specific voting instructions to your broker on how to vote your shares so that your vote can be counted.
Table of Contents
| PROXY SUMMARY | 1 | REPORT OF THE AUDIT COMMITTEE | 76 |
|---|---|---|---|
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS | 6 | AUDIT AND NON-AUDIT FEES | 77 |
| PROPOSAL 1Election of Directors | 9 | PROPOSAL 2Ratifying the Appointment of Independent Auditor and Authorizing the Audit Committee to Set Auditor Remuneration | 78 |
| Directors and Nominees | 10 | ||
| CORPORATE GOVERNANCE | 16 | PROPOSAL 3Advisory Resolution to Approve Named Executive Officer Compensation (Say-On-Pay) | 79 |
| Corporate Governance Principles | 16 | ||
| Board Performance Evaluations | 16 | ||
| Lead Independent Director and Chairman; Executive Sessions | 16 | ||
| Board Role in Risk Oversight | 17 | PROPOSAL 4Renewal of the Board’s Authority to Issue Shares Under Irish Law | 80 |
| Compensation Risk Assessment | 18 | ||
| Committees of the Board and Meetings | 22 | ||
| Director Independence | 27 | ||
| Related Party Transactions and Other Matters | 27 | PROPOSAL 5Renewal of the Board Authority to Opt Out of Statutory Pre-Emption Rights Under Irish Law | 81 |
| Complaint Procedure; Communications with Directors | 28 | ||
| Codes of Conduct | 28 | ||
| Director Compensation | 29 | ||
| Management | 32 | PROPOSAL 6Authorization of the Company and Any Subsidiary of the Company to Make Overseas Market Purchases of Medtronic Ordinary Shares | 83 |
| SHARE OWNERSHIP INFORMATION | 35 | ||
| Significant Shareholders | 35 | ||
| Beneficial Ownership of Management | 35 | ||
| COMPENSATION DISCUSSION AND ANALYSIS | 37 | QUESTIONS AND ANSWERS ABOUT THE ANNUAL GENERAL MEETING | 84 |
| Executive Summary | 38 | ||
| Process | 41 | Voting by Proxy | 84 |
| Fiscal Year 2026 Compensation Program Designs | 44 | How Proxies Will Be Voted | 84 |
| Fiscal Year 2026 Compensation Decisions | 45 | Voting at the Meeting | 84 |
| Executive Compensation Governance Practices and Policies | 51 | Admission to the Meeting | 85 |
| Other Benefits and Perquisites | 53 | ||
| OTHER INFORMATION | 86 | ||
| COMPENSATION AND TALENT COMMITTEE REPORT | 56 | Expenses of Solicitation | 86 |
| Shareholder Proposals and Director Nominations | 86 | ||
| EXECUTIVE COMPENSATION | 57 | Delivery of Documents to Shareholders Sharing an Address | 86 |
| 2026 Summary Compensation Table | 57 | Other | 87 |
| 2026 Grants of Plan-Based Awards | 60 | ||
| 2026 Awards at Fiscal Year End | 62 | APPENDIX A — Financial and Non-GAAP Reconciliations | A-1 |
| 2026 Option Exercises and Stock Vested | 64 | ||
| 2026 Pension Benefits | 65 | ||
| 2026 Nonqualified Deferred Compensation | 66 | ||
| Potential Payments Upon Termination or Change of Control | 68 | ||
| Equity Compensation Plan Information | 70 | ||
| 2026 CEO Pay Ratio | 71 | ||
| 2026 Pay Versus Performance | 71 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.